an emerging problem. J Pediatr 1984; 104: 206-10.
224
Tablan ОС, Martone WJ, Doershuk CF et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis.
225
Cystic Fibrosis Foundation. Patient registry annual data report 2012. Bethesda: Cystic Fibrosis Foundation; 2012. http://www.cff.org/UploadedFiles/research/Clinical Research/PatientRegistryReport/2012-CFF-Patient-Registry.pdf
226
European Cystic Fibrosis Society. ECFS patient registry. Annual data report 2010. Karup: European Cystic Fibrosis Society; 2010. https://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFSPR_Report10_v12014_final_020617.pdf
227
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.
228
Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacterid 1997; 47: 1188-200.
229
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.
230
Holmes A, Nolan R, Taylor R, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999; 179: 1197-205.
231
Sun L, Jiang RZ, Steinbach S, et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995; 1: 661-6.
232
Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 (Suppl 1):S1-S67.
233
Savant AP, O'Malley C, Bichl S, et al. Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. BMJ Quality Safety 2014;23(Suppl1):i73-i80.
234
Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8: 1025-30.
235
Murray S, Charbeneau J, Marshall ВС, et al. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J RespirCrit Care Med 2008; 178: 363-71.
236
Gilchrist FJ, Webb AK, Bright-Thomas RJ, et al. Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. J Cyst Fibros 2012; 11:458-60.
237
Uluer AZ, Waltz DA, Kalish LA, et al. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros 2013; 12:54-9.
238
Tullis DE, Burns JL, Retsch-Bogart GZ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014; 13: 296–305.
239
Horsley A, Jones AM. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev 2012; 10: CD009529.
240
Cystic Fibrosis Foundation. Patient registry annual data report 2012. Bethesda: Cystic Fibrosis Foundation; 2012. http://www.cff.org/UploadedFiles/research/Clinical Research/PatientRegistryReport/2012-CFF-Patient-Registry.pdf
241
Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008, Pediatr Pulmonol 2010; 45: 363-70.
242
Ridderberg W, Bendstrup KE, Olesen HV, et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 2011; 10:466-9.
243
Hansen CR, Pressler T, Ridderberg W, et al. Achromobacter species in cystic fibrosis: crossinfection caused by indirect patient-to-patient contact. J Cyst Fibros 2013; 12:609-15.
244
Ronne Hansen C, Pressler T, H0iby N, et al. Chronic infection with Achromobacter xylosoxidans'm cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006; 5: 245-51.
245
Amoureux L, Bador J, Siebor E, et al. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros 2013; 12: 170-6.
246
Jakobsen TH, Hansen MA, Jensen P0, et al. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PLoS One 2013; 8: e68484.
247
Raso T, Bianco O, Grosso B, et al. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS 2008; 116: 837-11.
248
Moissenet D, Baculard A, Valcin M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis 1997; 24: 274-5.
249
Kanellopoulou M, Pournaras S, Iglezos H, et al. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis 2004; 23: 336-9.
250
Hansen C, Pressler T, H0ibyN,et al. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006;5:245-51.
251
Magni A, Trancassmi M, Varesi P, et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients. J Clin Microbiol 2010; 48:1035-9.
252
Trancassini M, lebba V, Citera N, et al. Outbreak of Achromobarter xylosoxidans'm an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol 2014; 5: 138.
253
Magni A, Trancassmi M, Varesi P, et al. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients. J Clin Microbiol 2010; 48:1035-9.
254
European